Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21892191 
Choi JH, et al. (2011) Antidiabetic actions of a non-agonist PPARĪ³ ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-81 21892191
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Download Sites

S273-p - PPAR-gamma (human)
Orthologous residues
PPAR‑gamma (human): S273‑p, PPAR‑gamma iso2 (human): S245‑p, PPAR‑gamma iso3 (human): , PPAR‑gamma (mouse): S273‑p, PPAR‑gamma iso2 (mouse): S243‑p, PPAR‑gamma (rat): S273‑p
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  adipose tissue, MEF (fibroblast) [PPAR-gamma (mouse), homozygous knockout]
 Cellular systems studied:  primary cells, tissue
 Species studied:  mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK5 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
rosiglitazone TNF inhibit treatment-induced increase
SR1664 TNF inhibit treatment-induced increase
SR1824 TNF inhibit treatment-induced increase
SR1664 decrease in vivo (white adipose tissue)

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.